Frontlight ResearchEarly access
Taking peoplePhase 2
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
Key facts
- Who runs it
- Hamilton Health Sciences Corporation
- Where
- Canada17 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 120 people, planned
- Started
- 21 Mar 2025
- Expected to end
- 1 Jul 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tideglusib
- Placebo
- Record updated
- 12 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- A pathogenic or likely pathogenic desmosomal (PKP2, DSG2, DSC2, DSP, or JUP*) rare variant OR the TMEM43-p.S358L variant; *JUP carriers must be homozygous or compound heterozygous
- Mean ≥ 500 PVCs per 24 hours on a baseline screening 7-day Holter monitor
- Clinical ACM diagnosis or recognition of genetic carrier status for ≥ 6 months prior to screening
Who cannot take part
- Initiation, cessation, or dose change of a Class I or III anti-arrhythmic drug in the 3 months prior to screening
- Regular and long-term use of strong CYP3A4 inhibitors, including clarithromycin, telithromycin, ketoconazole, itraconazole, posaconazole, nefazodone, idinavir and ritonavir
- Concurrent use of drugs metabolized by CYP3A4 with a narrow therapeutic window e.g. warfarin and digoxin
- NYHA class IV heart failure
- Ventricular scar secondary to coronary artery disease
- Any potentially harmful chronic liver disease
- A history of alcohol or illicit substance use disorders
- Hypersensitivity to tideglusib or any components of its formulation, including allergy to strawberry
- ALT value > 2X the upper limit of the normal reference range at Screening
- Total bilirubin value greater than the upper limit of the normal reference range at Screening, unless documented Gilbert's syndrome. For individuals with Gilbert's syndrome, total bilirubin value greater than 2-fold the upper limit of the normal reference range at Screening
- Serum creatinine > 150 micromole/L or creatinine clearance ≤ 60 mL/min (according to Cockcroft-Gault formula) at Screening
- Pregnant at time of enrollment and women of childbearing age who do not use a highly effective form of contraception
- Males, engaged in sexual relations with a female of child-bearing potential, not using an acceptable contraceptive method if not surgically sterile
- Patients unwilling to provide informed consent or comply with follow-up
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.
The 2 groups in the trial
- TideglusibExisting treatment, for comparison
Randomization to Tideglusib 1g po daily or matching placebo
- PlaceboPlacebo, for comparison
Randomization to matching placebo 1g po daily
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Tailored therapeutics for cardiomyopathies.Nature reviews. Cardiology, 2025
- Record updated
- 12 March 2026